2024 -- S 2820 SUBSTITUTE A

========

LC004443/SUB A/2

========

     STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2024

____________

A N   A C T

RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT

     Introduced By: Senators Valverde, Euer, DiMario, and Miller

     Date Introduced: March 22, 2024

     Referred To: Senate Health & Human Services

     (Dept of Health)

It is enacted by the General Assembly as follows:

     SECTION 1. Section 21-28-2.1 of the General Laws in Chapter 21-28 entitled "Uniform

Controlled Substances Act" is hereby amended to read as follows:

     21-28-2.01. Authority to control — Registration requirements and procedures.

     (a)(1) The director of the department of health shall control all substances enumerated in § 

21-28-2.08 or the most current version of Title 21 of the Code of Federal Regulations (CFR) and

may by motion or on the petition of any interested party pursuant to the procedures of chapter 35

of title 42, the Administrative Procedures Act, add, reschedule, or delete a substance as a controlled

substance. In making this determination, the director of health shall consider, but not be limited to

the following:

     (i) ( Its actual or relative potential for abuse;

     (ii) Scientific evidence of its pharmacological effect if known;

     (iii) State of current scientific knowledge regarding the substance;

     (iv) Its history and current pattern of abuse;

     (v) The scope, duration, and significance of abuse;

     (vi) What, if any, risk there is to the public health;

     (vii) Its psychic or physiological dependence liability;

     (viii) Whether the substance is an immediate precursor of a substance already controlled

under this chapter.

     (2) After considering the factors in subdivision (1) of this section the director of health

shall make findings with respect to these factors and shall issue an order controlling the substance

if it is found that the substance has potential for abuse.

     (b) If the director of health designates a substance as an immediate precursor, substances

which are precursors of the controlled precursor shall not be subject to control solely because they

are precursors of the controlled precursor.

     (c) If any substance is designated, rescheduled, or deleted as a controlled substance under

federal law and notice of that action is given to the director of health, he or she shall similarly

control the substance under this chapter after the expiration of sixty (60) days from publication in

the federal register of a final order designating a substance as a controlled substance or rescheduling

or deleting a substance, unless within that sixty (60) day period, the director of health objects to

inclusion, rescheduling, or deletion. In that case, the director of health shall publish the reasons for

objection and afford all interested parties an opportunity to be heard. At the conclusion of the

hearing, the director of health shall publish his or her decision, which shall be final unless altered

by statute. The director of health shall publish and file his or her decision with the secretary of state.

Upon publication of objection to inclusion, rescheduling, or deletion under this chapter by the

director of health, control under this chapter is stayed until the director of health publishes his or

her decision. The director of the department of health shall reference the current version of Title 21

of the CFR as the current list of substances designated, rescheduled, or deleted as a controlled

substance for the state. If the director objects to inclusion, rescheduling, or deletion of any substance

under the current federal law, or if the director adds or reschedules a controlled substance pursuant

to the authority provided in this chapter, the director shall file that decision with the secretary of

state and post exempted substances on the department of health website.

     (d) The following persons need not register and may lawfully possess controlled substances

under this chapter:

     (1) An agent or employee of any registered manufacturer, distributor, or dispenser of any

controlled substance if he or she is acting in the usual course of his or her business or employment;

     (2) A common or contract carrier or warehouse operator, or an employee of a carrier or

warehouse operator, whose possession of any controlled substance is in the usual course of business

or employment;

     (3) An ultimate user or a person in possession of any controlled substance pursuant to a

lawful order of a practitioner or in lawful possession of a schedule V substance.

     (e) The director of health may waive by rule the requirement for registration of certain

manufacturers, distributors, or dispensers if he or she finds it consistent with the public health and

safety.

LC004443/SUB A/2 - Page 2 of 19

     (f) A separate registration is required at each place of business where the applicant

manufactures, distributes, or dispenses controlled substances. A separate registration is required at

each place of professional practice at which a practitioner stores controlled substances. A

practitioner may prescribe and administer controlled substances, upon registering with the director

of health at the applicant’s principal place of professional practice.

     (g) The director of health or his or her authorized agent may inspect the establishment of a

registrant or applicant for registration in accordance with his or her regulations.

     SECTION 2. Sections 21-28-2.8, 21-28-2.9 and 21-28-2.10 of the General Laws in Chapter

21-28 entitled "Uniform Controlled Substances Act" are hereby repealed.

     21-28-2.08. Contents of schedules.

     Schedules I through V shall consist of the drugs and other substances, by whatever official

name, common or usual name, chemical name, or brand name designated, listed in the

corresponding section, or designated by the director of the department of health pursuant to § 21-

28-2.01.

     Schedule I

     (a) Opiates. Unless specifically excepted or unless listed in another schedule, any of the

following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers

whenever the existence of the isomers, esters, ethers, and salts is possible within the specific

chemical designation:

     (1) Acetylmethadol

     (2) Allylprodine

     (3) Alphacetylmethadol

     (4) Alphameprodine

     (5) Alphamethadol

     (6) Benzethidine

     (7) Betacetylmethadol

     (8) Betameprodine

     (9) Betamethadol

     (10) Betaprodine

     (11) Clonitazene

     (12) Dextromoramide

     (13) Difenoxin

     (14) Diampromide

     (15) Diethylthiambutene

LC004443/SUB A/2 - Page 3 of 19

     (16) Dimenoxadol

     (17) Dimepheptanol

     (18) Dimethylthiambutene

     (19) Dioxaphetyl butyrate

     (20) Dipipanone

     (21) Ethylmethylthiambutene

     (22) Etonitazene

     (23) Extoxerdine

     (24) Furethidine

     (25) Hydroxypethidine

     (26) Ketobemidone

     (27) Levomoramide

     (28) Levophenacylmorphan

     (29) Morpheridine

     (30) Noracymethadol

     (31) Norlevorphanol

     (32) Normethadone

     (33) Norpipanone

     (34) Phenadoxone

     (35) Phenampromide

     (36) Phenomorphan

     (37) Phenoperidine

     (38) Piritramide

     (39) Proheptazine

     (40) Properidine

     (41) Propiram

     (42) Racemoramide

     (43) Trimeperidone

     (44) Tilidine

     (45) Alpha-methylfentanyl

     (46) Beta-hydroxy-3-methylfentanyl other names:

     N-[1-(2hydroxy-2-phenethyl)-3-methyl-4piperidingyl]-Nphenylpropanamide

     (47) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-

phenylpropanamide)

LC004443/SUB A/2 - Page 4 of 19

     (48) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its optical, positional, and

geometric isomers, salts and salts of isomers (Other names: acetyl fentanyl)

     (49) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenyl propionamide

(Other names: beta-hydroxythiofentanyl)

     (50) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide (Other names: Butyryl fentanyl)

     (51) N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (Other names: Furanyl

fentanyl)

     (52) 3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide (Other names: AH-

7921)

     (53) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (Other names:

U-47700)

     (54) 3-Methylbutyrfentanyl (Other names: 3-MBF)

     (55) 4-Fluorobutyrfentanyl (Other names: 4-FBF, p-FBF)

     (56) 4-Phenylfentanyl

     (57) 4-Methoxybutyrfentanyl (Other names: 4-MeO-BF)

     (58) Acrylfentanyl (Other names: acryloyfentanyl)

     (59) Lofentanyl

     (60) N-Methylcarfentanyl

     (61) Ocfentanyl (INN, A-3217)

     (63) 4-methoxymethylfentanyl (Other names: R-30490)

     (64) 1-cyclohexyl-4-(1,2 diphenylethyl)piperazine) (Other names: MT-45, IC-6)

     (b) Opium Derivatives. Unless specifically excepted or unless listed in another schedule,

any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the

existence of the salts, isomers, and salts of isomers is possible within the specific chemical

designation:

     (1) Acetorphine

     (2) Acetyldihydrocodeine

     (3) Benzylmorphine

     (4) Codeine methylbromide

     (5) Codeine-N-Oxide

     (6) Cyprenorphine

     (7) Desomorphine

     (8) Dihydromorphine

     (9) Etorphine (Except hydrochloride salt)

LC004443/SUB A/2 - Page 5 of 19

     (10) Heroin

     (11) Hydromorphinol

     (12) Methyldesorphine

     (13) Methylihydromorphine

     (14) Morphine methylbromide

     (15) Morphine methylsulfonate

     (16) Morphine-N-Oxide

     (17) Myrophine

     (18) Nococodeine

     (19) Nicomorphine

     (20) Normorphine

     (21) Pholcodine

     (22) Thebacon

     (23) Drotebanol

     (c) Hallucinogenic Substances. Unless specifically excepted or unless listed in another

schedule, any material, compound, mixture, or preparation that contains any quantity of the

following hallucinogenic substances, or that contains any of its salts, isomers, and salts of isomers

whenever the existence of the salts, isomers, and salts of isomers is possible within the specific

chemical designation (for purposes of this subsection only, the term “isomer” includes the optical,

position, and geometric isomers):

     (1) 3, 4-methylenedioxy amphetamine

     (2) 5-methoxy-3, 4-methylenedioxy amphetamine

     (3) 3, 4, 5-trimethoxy amphetamine

     (4) Bufotenine

     (5) Diethyltryptamine

     (6) Dimethyltryptamine

     (7) 4-methyl 2, 5-dimethoxyamphetamine

     (8) Ibogaine

     (9) Lysergic acid diethylamide

     (10) Marihuana

     (11) Mescaline

     (12) Peyote. Meaning all parts of the plant presently classified botanically as Lophophora

Williamsii Lemair whether growing or not; the seeds of the plant; any extract from any part of the

plant; and any compound, manufacture, salt, derivative, mixture, or preparation of the plant, its

LC004443/SUB A/2 - Page 6 of 19

seeds or extracts.

     (13) N-ethyl-3-piperidyl benzilate

     (14) N-methyl-3-piperidyl benzilate

     (15) Psilocybin

     (16) Psilocyn

     (17) Tetrahydrocannabinols. Synthetic equivalents of the substances contained in the plant,

or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their

isomers with similar chemical structure and pharmacological activity such as the following: delta

1 cis or trans tetrahydrocannabinol, and their optical isomers. Delta 6 cis or trans

tetrahydrocannabinol and their optical isomers. Delta 3, 4 cis or trans tetrahydrocannabinol and

their optical isomer. (Since nomenclature of these substances is not internationally standardized,

compounds of these structures, regardless of numerical designation of atomic positions covered).

     (18) Thiophene analog of phencyclidine. 1-(1-(2 thienyl) cyclo-hexyl) pipiridine: 2-

Thienyl analog of phencyclidine: TPCP

     (19) 2,5 dimethoxyamphetamine

     (20) 4-bromo-2,5-dimethoxyamphetamine, 4-bromo-2,5-dimethoxy-alpha-

methylphenethyamine: 4-bromo-2,5-DMA

     (21) 4-methoxyamphetamine-4-methoxy-alpha-methylphenethylaimine:

paramethoxyamphetamine: PMA

     (22) Ethylamine analog of phencyclidine. N-ethyl-1-phenylcyclohexylamine, (1-

phenylcyclohexyl) ethylamine, N-(1-phenylcyclophexyl) ethylamine, cyclohexamine, PCE

     (23) Pyrrolidine analog of phencyclidine. 1-(1-phencyclohexyl)-pyrrolidine PCPy, PHP

     (24) Parahexyl; some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-

trimethyl-6H-dibenz o (b,d) pyran: Synhexyl.

     (25) Salvia Divinorum (Salvinorin A or Divinorin A), meaning any extract from any part

of the plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall

not mean the unaltered plant.

     (26) Datura stamonium (jimsom weed or datura), meaning any extract from any part of the

plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall not mean

the unaltered plant.

     (d) Depressants. Unless specifically excepted or unless listed in another schedule, any

material, compound, mixture, or preparation that contains any quantity of the following substances

having a depressant effect on the central nervous system, including its salts, isomers, and salts of

isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the

LC004443/SUB A/2 - Page 7 of 19

specific chemical designation:

     (1) Mecloqualone.

     (2) Methaqualone.

     (3) 3-methyl fentanyl (n-(3methyl-1(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide.

     (4) 3,4-methyl-enedioxymethamphetamine (MDMA), its optical, positional, and geometric

isomers, salts, and salts of isomers.

     (5) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts, and salts

of isomers.

     (6) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP), its optical isomers, salts,

and salts of isomers.

     (7) N-(1-(1-methyl-2-phenyl)ethyl-4-piperidyl)-N-phenyl-acetamide (acetyl-

alphamethylfentanyl), its optical isomers, salts, and salts of isomers.

     (8) N-(1-(1-methyl-2(2-thienyl)ethyl-4-piperidyl)-N-phenylpropanami de (alpha-

methylthiofentanyl), its optical isomers, salts, and salts of isomers.

     (9) N-(1-benzyl-piperidyl)-N-phenylpropanamide (benzyl-fentanyl), its optical isomers,

salts, and salts of isomers.

     (10) N-(1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenyl-propanamid e (beta-

hydroxyfentanyl), its optical isomers, salts, and salts of isomers.

     (11) N-(3-methyl-1(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenylpro panamide (beta-

hydroxy-3-methylfentanyl), its optical and geometric isomers, salts, and salts of isomers.

     (12) N-(3-methyl)-1-(2-(2-thienyl)ethyl-4-piperidyl)-N-phenylpro-panamide (3-

methylthiofentanyl), its optical and geometric isomers, salts, and salts of isomers.

     (13) N-(1-2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its

optical isomers, salts, and salts of isomers.

     (14) N-(1-(2(2-thienyl)ethyl-4-piperidyl-N-phenylpropanamide (thiofentanyl), its optical

isomers, salts, and salts of isomers.

     (15) N-[1-(2-phenylethyl)-4-piperidyl]-N-(4-fluorophenyl)-propanamid e (para-

fluorofentanyl), its optical isomers, salts, and salts of isomers.

     (16) Gamma hydroxybutyrate, HOOC-CH2-CH2-CH2OH, its optical, position, or

geometric isomers, salts, and salts of isomers.

     (17) Etizolam.

     (18) Flubromazolam.

     (e) Stimulants. Unless specifically excepted or unless listed in another schedule, any

material, compound, mixture, or preparation that contains any quantity of the following substances

LC004443/SUB A/2 - Page 8 of 19

having a stimulant effect on the central nervous system, including its salts, isomers, and salts of

isomers:

     (1) Fenethylline

     (2) N-ethylamphetamine

     (3) 4-methyl-N-methylcathinone (Other name: mephedrone)

     (4) 3,4-methylenedioxy-N-methlycathinone (Other name: methylone)

     (5) 3,4-methylenedioxypyrovalerone (Other name: MDPV)

     (f) Any material, compound, mixture, or preparation that contains any quantity of the

following substances:

     (1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497)

     (2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol

(cannabicyclohexanol and CP-47,497 c8 homologue)

     (3) 1-Butyl-3-(1 naphthoyl)indole, (JWH-073)

     (4) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)

     (5) 1-Pentyl-3-(1-napthoyl)indole, (JWH-018 and AM678)

     (g) Synthetic cannabinoids or piperazines. Unless specifically excepted, any chemical

compound which is not approved by the United States Food and Drug Administration or, if

approved, which is not dispensed or possessed in accordance with state and federal law, that

contains Benzylpiperazine (BZP); Trifluoromethylphenylpiperazine (TFMPP); 1,1-

Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-naphthoyl) indole; 1-

Pentyl-3-(1-naphthoyl) indole; dexanabinol (HU-211); or any compound in the following structural

classes:

     (1) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with

substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl

group, whether or not further substituted in the indole ring to any extent and whether or not

substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not

limited, to JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, and AM-

2201;

     (2) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with

substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl

group whether or not further substituted in the indole ring to any extent and whether or not

substituted in the phenyl ring to any extent. Examples of this structural class include, but are not

LC004443/SUB A/2 - Page 9 of 19

limited to, JWH-167, JWH-250, JWH-251, and RCS-8;

     (3) Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with

substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl

group whether or not further substituted in the indole ring to any extent and whether or not

substituted in the phenyl ring to any extent. Examples of this structural class include, but are not

limited, to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4;

     (4) Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol

structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl

group whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural

class include, but are not limited to, CP 47,497 and its C8 homologue (cannabicyclohexanol);

     (5) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl)

methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,

alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-

morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and

whether or not substituted in the naphthyl ring to any extent. Examples of this structural class

include, but are not limited to, JWH-175, JWH-184, and JWH-185;

     (6) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure with

substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl

group whether or not further substituted in the pyrrole ring to any extent and whether or not

substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not

limited, to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

     (7) Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl)indene

structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl,

cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl

group whether or not further substituted in the indene ring to any extent and whether or not

substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not

limited to, JWH-176; or

     (8) Any other synthetic cannabinoid or piperazine which is not approved by the United

States Food and Drug Administration or, if approved, which is not dispensed or possessed in

accordance with state and federal law.

     (h) Synthetic cathinones. Unless specifically excepted, any chemical compound which is

LC004443/SUB A/2 - Page 10 of 19

not approved by the United States Food and Drug Administration or, if approved, which is not

dispensed or possessed in accordance with state and federal law, not including bupropion,

structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl,

naphthyl, or thiophene ring systems, whether or not the compound is further modified in one or

more of the following ways:

     (1) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,

haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by

one or more other univalent substituents. Examples of this class include, but are not limited to, 3,4-

Methylenedioxycathinone (bk-MDA);

     (2) By substitution at the 3-position with an acyclic alkyl substituent. Examples of this

class include, but are not limited to, 2-methylamino-1-phenylbutan-1-one (buphedrone);

     (3) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or

methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.

Examples of this class include, but are not limited to, Dimethylcathinone, Ethcathinone, and α-

Pyrrolidinopropiophenone (α-PPP); or

     (4) Any other synthetic cathinone which is not approved by the United States Food and

Drug Administration or, if approved, is not dispensed or possessed in accordance with state or

federal law. Examples of this class include, but are not limited to, Ephylone and Pentylone.

     Schedule II

     (a) Substances, vegetable origin, or chemical synthesis. Unless specifically excepted or

unless listed in another schedule, any of the following substances whether produced directly or

indirectly by extraction from substances of vegetable origin, or independently by means of

chemical synthesis, or by a combination of extraction and chemical synthesis:

     (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or

opiate excluding naloxone and its salts, and excluding naltrexone and its salts, but including the

following:

     (i) Raw opium

     (ii) Opium extracts

     (iii) Opium fluid extracts

     (iv) Powdered opium

     (v) Granulated opium

     (vi) Tincture of opium

     (vii) Etorphine hydrochloride

     (viii) Codeine

LC004443/SUB A/2 - Page 11 of 19

     (ix) Ethylmorphine

     (x) Hydrocodone

     (xi) Hydromorphone

     (xii) Metopon

     (xiii) Morphine

     (xiv) Oxycodone

     (xv) Oxymorphone

     (xvi) Thebaine

     (2) Any salt, compound, derivative, or preparation that is chemically equivalent or identical

with any of the substances referred to in subdivision (1) of this subsection, except that these

substances shall not include the isoquinoline alkaloids of opium.

     (3) Opium poppy and poppy straw.

     (4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any

salt, compound, derivative, or preparation that is chemically equivalent or identical with any of

these substances, except that the substances shall not include decocainized coca leaves or extraction

of coca leaves, which extractions do not contain cocaine or ecgonine.

     (5) Concentrate of poppy straw (the crude extract of poppy straw in liquid, solid, or powder

form that contains the phenanthrine alkaloids of the opium poppy).

     (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the

following opiates, including its isomers, esters, ethers, salts; and salts of isomers, esters, and ethers

whenever the existence of the isomers, esters, ethers, and salts is possible within the specific

chemical designation:

     (1) Alphaprodine

     (2) Anileridine

     (3) Bezitramide

     (4) Dihydrocodeine

     (5) Diphenoxylate

     (6) Fentanyl

     (7) Isomethadone

     (8) Levomethorphan

     (9) Levorphanol

     (10) Metazocine

     (11) Methadone

     (12) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane

LC004443/SUB A/2 - Page 12 of 19

     (13) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic

acid

     (14) Pethidine

     (15) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine

     (16) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate

     (17) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid

     (18) Phenaxocine

     (19) Piminodine

     (20) Racemethorphan

     (21) Racemorphan

     (22) Bulk Dextropropoxyphene (non-dosage forms)

     (23) Suffentanil

     (24) Alfentanil

     (25) Levoalphacetylmethadol

     (26) Carfentanil

     (27) Remifentanil

     (c) Stimulants. Unless specifically excepted or unless listed in another schedule, any

material, compound, mixture, or preparation that contains any quantity of the following substances

having a stimulant effect on the central nervous system:

     (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers.

     (2) Methamphetamine, its salts, and salts of its isomers.

     (3) Phenmetrazine and its salts.

     (4) Methylphenidate.

     (d) Depressants. Unless specifically excepted or unless listed in another schedule, any

material, compound, mixture, or preparation that contains any quantity of the following substances

having a depressant effect on the central nervous system, including its salts, isomers, and salts of

isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the

specific chemical designation:

     (1) Amobarbital

     (2) Glutethimide

     (3) Methyprylon

     (4) Pentobarbital

     (5) Phencyclidine

     (6) Secobarbital

LC004443/SUB A/2 - Page 13 of 19

     (7) Phencyclidine immediate precursors:

     (i) 1-phencyclohexylamine

     (ii) 1-piperidinocyclohexane-carbonitrile (PCC)

     (8) Immediate precursor to amphetamine and methamphetamine: Phenylacetone. Some

other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzone ketone.

     Schedule III

     (a) Unless specifically excepted or unless listed in another schedule, any material,

compound, mixture, or preparation that contains any quantity of the following substances having a

depressant effect on the central nervous system:

     (1) Any substance that contains any quantity of a derivative of barbituric acid or any salt

of a derivative of barbituric acid.

     (2) Chlorhexadol

     (3) Lysergic acid

     (4) Lysergic acid amide

     (5) Sulfondiethylmethane

     (6) Sulfonethylmethane

     (7) Sylfonmethane

     (8) Any compound, mixture, or preparation containing amobarbital, secobarbital,

pentobarbital, or any salt of them and one or more other active medicinal ingredients that are not

listed in any schedule.

     (9) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or

any salt of any of these drugs and approved by the Food and Drug Administration for marketing

only as a suppository.

     (10) Ketamine, its salts, isomers, and salts of isomers. (Some other names for ketamine:

(+)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone).

     (b) Unless specifically excepted or unless listed in another schedule, any material,

compound, mixture, or preparation containing limited quantities of any of the following narcotic

drugs, or any salts of them:

     (1) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred

milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with an equal

or greater quantity of an isoquinoline alkaloid of opium.

     (2) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred

milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or

more active, nonnarcotic ingredients in recognized therapeutic amounts.

LC004443/SUB A/2 - Page 14 of 19

     (3) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one

hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with

a fourfold or greater quantity of an isoquinoline alkaloid of opium.

     (4) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one

hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with

one or more active nonnarcotic ingredients in recognized therapeutic amounts.

     (5) Not more than one and eight tenths grams (1.8 gms.) of dihydrocodeine per one hundred

milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or

more active nonnarcotic ingredients in recognized therapeutic amounts.

     (6) Not more than three hundred milligrams (300 mgs.) of ethylmorphine per one hundred

milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with one or

more active nonnarcotic ingredients in recognized therapeutic amounts.

     (7) Not more than five hundred milligrams (500 mgs.) of opium per one hundred milliliters

(100 mls.) or per one hundred grams (100 gms.) or not more than twenty-five milligrams (25 mgs.)

per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.

     (8) Not more than fifty milligrams (50 mgs.) of morphine per one hundred milliliters (100

mls.) per one hundred grams (100 gms.) with one or more active, nonnarcotic ingredients in

recognized therapeutic amounts.

     (c) Stimulants. Unless specifically excepted or listed in another schedule, any material,

compound, mixture, or preparation that contains any quantity of the following substances having a

stimulant effect on the central nervous system, including its salts, isomers, and salts of the isomers

whenever the existence of the salts of isomers is possible within the specific chemical designation:

     (1) Benzphetamine

     (2) Chlorphentermine

     (3) Clortermine

     (4) Mazindol

     (5) Phendimetrazine

     (d) Steroids and hormones. Anabolic steroids (AS) or human growth hormone (HGH),

excluding those compounds, mixtures, or preparations containing an anabolic steroid that because

of its concentration, preparation, mixture, or delivery system, has no significant potential for abuse,

as published in 21 C.F.R. § 1308.34, including, but not limited to, the following:

     (1) Chorionic gonadotropin, except for veterinary use and when that use is approved by the

Food and Drug Administration.

     (2) Clostebol

LC004443/SUB A/2 - Page 15 of 19

     (3) Dehydrochlormethyltestosterone

     (4) Ethylestrenol

     (5) Fluoxymesterone

     (6) Mesterolone

     (7) Metenolone

     (8) Methandienone

     (9) Methandrostenolone

     (10) Methyltestosterone

     (11) Nandrolone decanoate

     (12) Nandrolone phenpropionate

     (13) Norethandrolone

     (14) Oxandrolone

     (15) Oxymesterone

     (16) Oxymetholone

     (17) Stanozolol

     (18) Testosterone propionate

     (19) Testosterone-like related compounds

     (20) Human Growth Hormone (HGH)

     (e) Hallucinogenic substances.

     (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in U.S.

Food and Drug Administration-approved drug product. (Some other names for dronabinol: (6aR-

trans)-6a, 7, 8, 10a-tetrahydro-6, 6, 9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)-delta-

9(trans)-tetrahydrocannabinol.)

     Schedule IV

     (1) Barbital.

     (2) Chloral betaine

     (3) Chloral hydrate

     (4) Ethchrovynol

     (5) Ethinamate

     (6) Methohexital

     (7) Meprobamate

     (8) Methylphenobarbital

     (9) Paraldehyde

     (10) Petrichloral

LC004443/SUB A/2 - Page 16 of 19

     (11) Phenobarbital

     (12) Fenfluramine

     (13) Diethylpropion

     (14) Phentermine

     (15) Pemoline (including organometallic complexes and chelates thereof).

     (16) Chlordiazepoxide

     (17) Clonazepam

     (18) Clorazepate

     (19) Diazepam

     (20) Flurazepam

     (21) Mebutamate

     (22) Oxazepam

     (23) Unless specifically excepted or unless listed in another schedule, any material,

compound, mixture, or preparation that contains any quantity of the following substances, including

its salts:

     Dextropropoxyphene(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-

propronoxybutane).

     (24) Prazepam

     (25) Lorazepam

     (26) Not more than one milligram (1 mg.) of difenoxin and not less than twenty-five (25)

micrograms of atropine sulfate per dosage unit.

     (27) Pentazocine

     (28) Pipradrol

     (29) SPA (-)-1-dimethylamino-1, 2-diphenylethane

     (30) Temazepam

     (31) Halazepam

     (32) Alprazolam

     (33) Bromazepam

     (34) Camazepam

     (35) Clobazam

     (36) Clotiazepam

     (37) Cloxazolam

     (38) Delorazepam

     (39) Estazolam

LC004443/SUB A/2 - Page 17 of 19

     (40) Ethyl Ioflazepate

     (41) Fludizaepam

     (42) Flunitrazepam

     (43) Haloxazolam

     (44) Ketazolam

     (45) Loprazolam

     (46) Lormetazepam

     (47) Medazepam

     (48) Nimetazepam

     (49) Nitrazepam

     (50) Nordiazepam

     (51) Oxazolam

     (52) Pinazepam

     (53) Tetrazepam

     (54) Mazindol

     (55) Triazolam

     (56) Midazolam

     (57) Quazepam

     (58) Butorphanol

     (59) Sibutramine

     (60) Tramadol

     (61) Zolpidem

     Schedule V

     (a) Any compound, mixture, or preparation containing any of the following limited

quantities of narcotic drugs, which shall include one or more non-narcotic active medicinal

ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable

medicinal qualities other than those possessed by the narcotic drug alone:

     (1) Not more than two hundred milligrams (200 mgs.) of codeine per 100 milliliters (100

mls.) or per one hundred grams (100 gms.).

     (2) Not more than one hundred milligrams (100 mgs.) of dihydrocodeine per 100 milliliters

(100 mls.) or per one hundred grams (100 gms.).

     (3) Not more than one hundred milligrams (100 mgs.) of ethylmorphine per 100 milliliters

(100 mls.) or per one hundred grams (100 gms.).

     (4) Not more than two and five tenths milligrams (2.5 mgs.) of diphenixylate and not less

LC004443/SUB A/2 - Page 18 of 19

than twenty-five (25) micrograms of atropine sulfate per dosage unit.

     (5) Not more than one hundred milligrams (100 mgs.) of opium per one hundred milliliters

(100 mls.) or per one hundred grams (100 gms.).

     (b) Not more than five tenths milligrams (0.5 mgs.) of difenoxin and not less than twenty-

five (25) micrograms of atropine sulfate per dosage unit.

     (c) Buprenorphine

     (d) Unless specifically exempted or excluded or unless listed in another schedule, any

material, compound, mixture, or preparation that contains any quantity of the following substances

having a stimulant effect on the central nervous system, including its salts, isomers, and salts of

isomers:

     (1) Propylhexedrine (except as benzedrex inhaler)

     (2) Pyrovalerone.

     (e) Xylazine HCL

     21-28-2.09. Exemption of compounds containing counteragents.

     Nothing in this chapter shall apply to any compound, mixture, or preparation containing

any depressant or stimulant drug in schedule II or in subsection (a) of schedule III or in schedule

IV or V if: (1) the compound, mixture, or preparation contains one or more active medicinal

ingredients not having a depressant or stimulant effect on the central nervous system, and (2) these

ingredients are included in the compound, mixture or preparation in such combinations, quantity,

proportion, or concentration as to vitiate the potential for abuse of the drugs which do have a

depressant or stimulant effect on the central nervous system.

     21-28-2.10. Exemption of dextromethorphan.

     Dextromethorphan shall not be deemed to be included in any schedule unless controlled

pursuant to the provisions of this article.

     SECTION 3. This act shall take effect on February 1, 2025.

========

LC004443/SUB A/2

========

LC004443/SUB A/2 - Page 19 of 19

EXPLANATION

BY THE LEGISLATIVE COUNCIL

OF

A N   A C T

RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT

***

     This act would substitute the current lists of controlled substances in the general laws with

the current version of Title 21 of the code of federal regulations.

     This act would take effect on February 1, 2025.

========

LC004443/SUB A/2

========

LC004443/SUB A/2 - Page 20 of 19